期刊文献+

纳米碳甲状旁腺负显影在甲状腺癌手术中的应用分析 被引量:6

Application of Negative Stained Parathyroid in Thyroid Carcinoma Surgery by Using Carbon Nanoparticles
下载PDF
导出
摘要 目的:探讨在甲状腺癌手术中采用纳米碳淋巴示踪剂保护甲状旁腺的作用。方法:245例甲状腺癌患者随机均分为常规组和纳米碳组,比较两组中央区淋巴结脂肪组织中误切的甲状旁腺检获情况及术后血钙、甲状旁腺素(PTH)改变情况。结果:纳米碳组一过性低钙血症症状发生率13.33%明显低于常规组32.90%,差异具有统计学意义(P<0.05);纳米碳组永久性低钙血症发生率0,常规组1.29%,差异无统计学意义(P>0.05);纳米碳组PTH暂时性减低发生率11.11%低于常规组29.68%,差异具有统计学意义(P<0.05)。PTH永久性减低纳米碳组未发生,常规组1.29%,差异无统计学意义(P>0.05)。病理检查证实纳米碳组检获误切甲状旁腺率4.44%明显低于常规组12.90%,差异具有统计学意义(P<0.05)。结论:应用纳米碳负显影在甲状腺癌手术中可起到辨认和保护甲状旁腺的作用。 Objective To investigate the role of carbon nanoparticles lymphatic tracer in the protection of parathyroid gland in thyroid carcinoma. Methods 245 cases of thyroid cancer patients were randomly divided into the routine group and carbon nanoparticles group, the mistakenly cut rate of parathyroid, postoperative serum level of calcium and parathyroid hormone(PTH) changes were compared between the two groups Results The transient hypocalcemia occurred in carbon nanoparticles group is 12 cases(12 / 90, 13.33 %), while in routine group is 51 cases(51/155,32.90 %), which is statistically significant(χ2= 11.416, P = 0.01 0.05); permanent hypocalcemia did not occurred in the carbon nanoparticles group, while in the routine group were 2 cases(2/155,1.29 %), which is no statistical significance. The occurrence of PTH temporarily reduction in carbon nanoparticles group is 10 cases(10 / 90, 11.11 %), wihle in routine group is 46 cases(46/155 29.68 %), which is statistically significant(χ2 = 11.131, P = 0.01 0.05). The PTH permanent reduction did not happened in carbon nanoparticles group, while in routine group is 2 cases(2/155,1.29%), which is not statistically significant. The mistakenly cut of parathyroid confirmed by inspection is 4 cases in carbon nanoparticles group( 4/90,4.44 %)and 20 in routine group(20/155 and 12.90 %), which is statistical significance χ2 = 4.611, P = 0.032 0.05).Conclusion :The application of lymphatic mapping to recognize and protect negative stained parathyroid in thyroid carcinoma surgery by using carbon nanoparticles.
出处 《深圳中西医结合杂志》 2015年第18期6-9,共4页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
基金 深圳市科技计划项目(201302083)
关键词 甲状腺癌 甲状旁腺 纳米碳 颈淋巴结清扫术 Thyroid carcinoma Parathyroid gland Carbon nanoparticles Neck dissection
  • 相关文献

参考文献8

  • 1王先明,吴恢升,王敏,陈伟财.分化型甲状腺癌的风险评估和个体化治疗策略[J].医学与哲学(B),2012,33(10):9-10. 被引量:5
  • 2吴恢升,何劲松,陈伟财,王先明.选择性颈淋巴结清除术在乳头状甲状腺癌手术治疗的临床应用[J].中国普通外科杂志,2012,21(5):532-535. 被引量:17
  • 3Sen WT, Ogawa L,Ruan D,et al.Central neck lymph node dissection for papillary thyroid cancer:comparison of complication and recurrence rates in 295 initial dissections and reoperations[J].Arch Surg,2010,145(3):272-275.
  • 4Moo TA,McGill J,Allendorf J,et al.Impact of prophylactic centralneck lymph node dissection on early recurrence in papillarythyroid carcinoma [J].World J Surg,2010,34(6):l187-1191.
  • 5Lveryd A.Parathyroid glands in thyroid surgery:anatomy of parathyroid glands: II postoperative hypoparathyroaidism identification and autotransplantation of parathyroid glands [J]. Acta Chir Scand,1986,389:1-120.
  • 6孙辉,刘晓莉.甲状腺癌规范化诊治理念更新及其意义[J].中国实用外科杂志,2015,35(1):72-75. 被引量:73
  • 7Kihara M,M iyauchi A,Kontani K,et al .Recovery of parathyroid function after total thyroidectomy:longterm follow--up study [J].ANZ J Surg,2005,75(7):532-536.
  • 8Yang F, Jin C,Yang D,et al.Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment [J]. Eur J Cancer,2011,47(12): 1873-1882.

二级参考文献29

  • 1李树玲.我国甲状腺癌外科现状与展望[J].临床外科杂志,2006,14(3):129-130. 被引量:46
  • 2Palazzo FF, Gosnell J, Savio R. Lymphadenectomy for papillarythyroid cancer: changes in practice over four decades[J]. Eur J Surg Oncol, 2006, 32(3):340-344.
  • 3Sobin LH, Wittekind CH. TNM classification of malignant tumors[M]. 6th Edition. USA:Wiley-Liss, New York, 2002:52-56.
  • 4Robbins KT, Clayman G, Levine PA, et al. Neck dissection classification updates: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology- Head and Neck Surgery[J]. Arch Otolaryngol Head Neck Surg, 2002, 128(7):751-758.
  • 5Guideline of thyroid cancer:in clinical practice guidelines in oncology,version 1, 2010, National Comprehensive Cancer Network (NCCN).
  • 6Guidelines for the management of thyroid cancer in adults.2007. British Thyroid Association and Royal College of Physicians,London.
  • 7Caron NR, Tan YY, Ogilivie JB, et al. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary?[J]. World J Surg, 2006, 30(5):833- 840.
  • 8Kupferman ME, Weinstock YE, Santillan AA, et al. Predictors of level V metastasis in well-differentiated thyroid cancer[J].Head Neck, 2008, 30(11):1469-1474.
  • 9Noguchi S, Clark OH, Noguchi S. thyroid cancer: diagnosis and treatment[M]. 1st edition, missouri: quality medical publishing, 2000:257-273.
  • 10Kupferman M E,Weinstock Y E,Santillan A A,et al. Predictors of level V metastasis in well differentiated thyroid cancer[J]. Head Neck,2008,30(11): 1469-1474.

共引文献91

同被引文献36

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部